AbbVie Inc. (ABBV) FY2025 Annual P&L / Income Statement

AbbVie Inc. (ABBV) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

61,160,000,000 US dollars

Cost of products sold

18,204,000,000 US dollars

Gross profit (calculated)

42,956,000,000 US dollars

Operating expenses (calculated)

27,881,000,000 US dollars

Operating earnings

15,075,000,000 US dollars

Other income (expense), net (calculated)

negative 8,478,000,000 US dollars

Earnings before income tax expense

6,597,000,000 US dollars

Income tax expense (benefit)

2,364,000,000 US dollars

Net earnings

4,233,000,000 US dollars

UNITED STATES

46,603,000,000 US dollars

GERMANY

1,738,000,000 US dollars

JAPAN

1,274,000,000 US dollars

CANADA

1,222,000,000 US dollars

CHINA

1,006,000,000 US dollars

FRANCE

806,000,000 US dollars

UNITED KINGDOM

626,000,000 US dollars

SPAIN

609,000,000 US dollars

ITALY

580,000,000 US dollars

BRAZIL

478,000,000 US dollars

AUSTRALIA

459,000,000 US dollars

All other countries

5,759,000,000 US dollars

Selling, general and administrative

14,010,000,000 US dollars

Research and development

9,096,000,000 US dollars

Acquired IPR&D and milestones

5,016,000,000 US dollars

Other operating income

negative 241,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.23 B; to noncontrolling interests: $7.00 M.